Home » Stocks » Liminal BioSciences

Liminal BioSciences Inc. (LMNL)

Stock Price: $12.49 USD -0.38 (-2.95%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Pre-market: $12.50 +0.01 (0.08%) Jul 10, 5:54 PM

Stock Price Chart

Key Info

Market Cap 292.52M
Revenue (ttm) 3.74M
Net Income (ttm) -158.62M
Shares Out 23.42M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $12.49
Previous Close $12.87
Change ($) -0.38
Change (%) -2.95%
Day's Open 12.76
Day's Range 12.15 - 13.00
Day's Volume 28,932
52-Week Range 7.33 - 31.45

More Stats

Market Cap 292.52M
Enterprise Value 281.67M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 23.42M
Float 3.38M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -4.94
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 40,829
Short Ratio 2.31
Short % of Float 1.21%
Beta 1.58
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 78.14
PB Ratio 2.99
Revenue 3.74M
Operating Income -99.71M
Net Income -158.62M
Free Cash Flow -79.26M
Net Cash 10.85M
Net Cash / Share 0.47
Gross Margin 43.66%
Operating Margin -2,663.58%
Profit Margin -4,237.30%
FCF Margin -2,117.33%
ROA -55.46%
ROE -390.87%
ROIC -141.90%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions CAD.

Financial Overview

Year201920182017
Revenue4.9024.6322.31
Revenue Growth-80.09%10.4%-
Gross Profit2.14-1.0718.62
Operating Income-131-265-125
Net Income-208-280-130
Shares Outstanding16.060.830.80
Earnings Per Share-12.81-235.95-137.85
Operating Cash Flow-99.39-82.45-123
Capital Expenditures-4.44-5.13-10.08
Free Cash Flow-104-87.58-133
Cash & Equivalents61.297.3938.87
Total Debt47.0712849.12
Net Cash / Debt14.21-120-10.25
Assets165103265
Liabilities70.16166106
Book Value102-56.60132
Numbers in millions CAD, except per-share numbers.

Company Profile

Company Details

Full Name Liminal BioSciences Inc.
Country Canada
Employees 300
CEO Kenneth Harry Galbraith

Stock Information

Ticker Symbol LMNL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LMNL

Description

Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.